Amryt Pharma plc [AMYT] vs Eli Lilly and [LLY] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 21 vital metrics comparison: Amryt Pharma plc wins in 5 metrics, Eli Lilly and Company wins in 8 metrics, with 2 ties. Eli Lilly and Company appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amryt Pharma plc | Eli Lilly and Company | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 39.73 | 40.09 | Amryt Pharma plc |
| Price-to-Book Ratio | 2.80 | 31.01 | Amryt Pharma plc |
| Debt-to-Equity Ratio | 164.32 | 165.31 | Amryt Pharma plc |
| PEG Ratio | -0.39 | 0.79 | Eli Lilly and Company |
| EV/EBITDA | 0.00 | 26.61 | Tie |
| Profit Margin (TTM) | 52.32% | 31.67% | Amryt Pharma plc |
| Operating Margin (TTM) | -0.86% | 44.90% | Eli Lilly and Company |
| EBITDA Margin (TTM) | N/A | 44.90% | N/A |
| Return on Equity | -94.18% | 101.16% | Eli Lilly and Company |
| Return on Assets (TTM) | -2.32% | 19.42% | Eli Lilly and Company |
| Free Cash Flow (TTM) | N/A | $5.96B | N/A |
| Dividend Yield | N/A | 0.60% | N/A |
| 1-Year Return | N/A | 38.28% | N/A |
| Price-to-Sales Ratio (TTM) | 4.24 | 12.63 | Amryt Pharma plc |
| Enterprise Value | $0 | $843.37B | Eli Lilly and Company |
| EV/Revenue Ratio | 0.00 | 12.94 | Tie |
| Gross Profit Margin (TTM) | 44.86% | 82.52% | Eli Lilly and Company |
| Revenue per Share (TTM) | $5 | $73 | Eli Lilly and Company |
| Earnings per Share (Diluted) | $0.02 | $22.94 | Eli Lilly and Company |
| Beta (Stock Volatility) | N/A | 0.50 | N/A |
| Short % of Float | N/A | 0.97% | N/A |
Amryt Pharma plc vs Eli Lilly and Company Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amryt Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Eli Lilly and Company | -0.32% | -1.72% | 12.38% | 14.18% | 6.32% | 4.53% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amryt Pharma plc | N/A | N/A | N/A | N/A | N/A | N/A |
| Eli Lilly and Company | 38.28% | 153.07% | 418.42% | 1,433.98% | 2,935.09% | 1,988.48% |
Performance & Financial Health Analysis: Amryt Pharma plc vs Eli Lilly and Company
| Metric | AMYT | LLY |
|---|---|---|
| Market Information | ||
| Market Cap | N/A | $821.31B |
| Market Cap Category | N/A | Mega cap |
| 10 Day Avg. Volume | 2,376,385 | 2,387,476 |
| 90 Day Avg. Volume | 1,458,182 | 2,777,749 |
| Last Close | $14.70 | $1,129.35 |
| 52 Week Range | $14.70 - $14.71 | $623.78 - $1,182.73 |
| % from 52W High | -0.07% | -4.51% |
| All-Time High | $14.71 (Jan 16, 2025) | $1,182.73 (Jun 08, 2026) |
| % from All-Time High | -0.07% | -4.51% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.11% | 0.43% |
| Quarterly Earnings Growth | N/A | 0.51% |
| Financial Health | ||
| Profit Margin (TTM) | 0.52% | 0.32% |
| Operating Margin (TTM) | -0.01% | 0.45% |
| Return on Equity (TTM) | -0.94% | 1.01% |
| Debt to Equity (MRQ) | 164.32 | 165.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.02 | $29.66 |
| Cash per Share (MRQ) | $1.30 | $8.14 |
| Operating Cash Flow (TTM) | $-29,023,000 | $16.81B |
| Levered Free Cash Flow (TTM) | $-18,171,000 | $1.95B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.60% |
| Last 12-Month Dividend | N/A | $6.23 |
Valuation & Enterprise Metrics Analysis: Amryt Pharma plc vs Eli Lilly and Company
| Metric | AMYT (Mar 31, 2025) | LLY (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 39.73 | 40.09 |
| Forward P/E | -490.00 | 21.82 |
| PEG Ratio | -0.39 | 0.79 |
| Price to Sales (TTM) | 4.24 | 12.63 |
| Price to Book (MRQ) | 2.80 | 31.01 |
| Market Capitalization | ||
| Market Capitalization | $942.77M | $821.31B |
| Enterprise Value | $0 | $843.37B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.00 | 12.94 |
| Enterprise to EBITDA | 0.00 | 26.61 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.50 |
| Book Value per Share (MRQ) | $0.02 | $29.66 |
Financial Statements Comparison: Amryt Pharma plc vs Eli Lilly and Company
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | AMYT | LLY (2025) |
|---|---|---|
| Revenue/Sales | N/A | 65.18B |
| Cost of Goods Sold | N/A | 11.05B |
| COGS % of Revenue | - | 17.0% |
| Gross Profit | N/A | 54.13B |
| Gross Margin | - | 83.0% |
| Research & Development | N/A | 13.34B |
| Operating Income (EBIT) | N/A | 29.70B |
| Operating Margin | - | 45.6% |
| EBITDA | N/A | 35.09B |
| EBITDA Margin | - | 53.8% |
| Pre-Tax Income | N/A | 25.73B |
| Pre-Tax Income % of Revenue | - | 39.5% |
| Income Tax | N/A | 5.09B |
| Income Tax % of Revenue | - | 7.8% |
| Net Income (Profit) | N/A | 20.64B |
| Profit Margin | - | 31.7% |
Balance Sheet & Liquidity Metrics
| Metric | AMYT | LLY (2025) |
|---|---|---|
| Cash & Equivalents | N/A | 7.27B |
| Total Current Assets | N/A | 55.63B |
| Total Current Assets % of Revenue | - | 85.3% |
| Total Current Liabilities | N/A | 35.23B |
| Total Current Liabilities % of Revenue | - | 54.0% |
| Long-Term Debt | N/A | 40.87B |
| Long-Term Debt % of Revenue | - | 62.7% |
| Total Shareholders Equity | N/A | 26.54B |
| Retained Earnings | N/A | 24.47B |
| Retained Earnings % of Revenue | - | 37.5% |
| Property, Plant & Equipment | N/A | 13.49B |
Cash Flow Statement Comparison
| Metric | AMYT | LLY (2025) |
|---|---|---|
| Operating Cash Flow | N/A | 23.60B |
| Operating Cash Flow % of Revenue | - | 36.2% |
| Capital Expenditures | N/A | -7.84B |
| Free Cash Flow | N/A | 5.96B |
| FCF Margin | - | 9.2% |
| Debt Repayment | N/A | -778.00M |
| Common Stock Repurchase | N/A | -4.11B |
Short Interest & Institutional Ownership Analysis
| Metric | AMYT | LLY |
|---|---|---|
| Shares Short | N/A | 7.70M |
| Short Ratio | N/A | 2.73 |
| Short % of Float | N/A | 0.97% |
| Shares Outstanding | 64.13M | 894.80M |
| Float Shares | N/A | 890.99M |
| % Held by Insiders | N/A | 0.17% |
| % Held by Institutions | N/A | 84.77% |
| % Held by Public | N/A | 15.06% |
Dividend Analysis & Yield Comparison: Amryt Pharma plc vs Eli Lilly and Company
| Metric | AMYT | LLY |
|---|---|---|
| Last 12-Month Dividend | N/A | $6.23 |
| Last 12-Month Dividend Yield | N/A | 0.60% |
| 3-Year Avg Annual Dividend | N/A | $5.44 |
| 3-Year Avg Dividend Yield | N/A | 0.18% |
| 3-Year Total Dividends | N/A | $16.32 |
| Ex-Dividend Date | N/A | Feb 13, 2026 |